Cambridge synthetic biology doyen Constructive Bio has been awarded a significant grant from Innovate UK to transform the ...

Novo Nordisk NVO announced that it is launching a new direct-to-patient online pharmacy called NovoCare, which will offer its ...

Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of ...

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese people without diabetes and another one for people with diabetes.

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

Studies suggest types of fasting can lead to moderate weight loss and other health benefits in overweight and obese people, ...

Following consumer complaints, the manufacturers of weight loss drugs Wegovy and Zepbound have announced significant price drops in a move that could allow more Americans to access those medications.

Shares of Hims & Hers (HIMS) are down $3.47, or 8%, to $37.50 in pre-market trading after a court denied a motion for a preliminary ...

"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...

The FDA recently announced that Novo Nordisk’s semaglutide GLP-1 medication (Ozempic and Wegovy) is no longer in short supply ...

U.S. taxpayers spent billions developing Ozempic-type diabetes and weight-loss drugs — now those drugs’ markups could ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...